Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.9% – Time to Buy?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares rose 7.9% during trading on Friday . The company traded as high as $14.82 and last traded at $14.7450. Approximately 386,495 shares traded hands during trading, a decline of 64% from the average daily volume of 1,087,490 shares. The stock had previously closed at $13.67.

Wall Street Analysts Forecast Growth

AVTX has been the topic of a number of research analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Mizuho upped their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Wolfe Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target on the stock. Bank of America initiated coverage on shares of Avalo Therapeutics in a research report on Friday. They set a “buy” rating and a $35.00 price target on the stock. Finally, Weiss Ratings cut shares of Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Avalo Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $46.67.

Avalo Therapeutics Stock Up 7.0%

The stock has a market capitalization of $769.04 million, a P/E ratio of -2.68 and a beta of 0.83. The firm’s 50 day simple moving average is $15.72 and its two-hundred day simple moving average is $16.22.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, equities research analysts expect that Avalo Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the sale, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $13.23, for a total transaction of $111,886.11. Following the sale, the chief financial officer directly owned 423 shares of the company’s stock, valued at approximately $5,596.29. The trade was a 95.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 138,078 shares of company stock valued at $2,501,346. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. PFS Partners LLC increased its position in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after acquiring an additional 1,000 shares in the last quarter. BIT Capital GmbH bought a new stake in shares of Avalo Therapeutics during the third quarter worth about $25,000. Geode Capital Management LLC increased its position in shares of Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after acquiring an additional 2,648 shares in the last quarter. Glenmede Trust Co. NA increased its position in shares of Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock worth $384,000 after acquiring an additional 5,280 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics during the third quarter worth about $143,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.